BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...finance biotechs, especially the more mature rounds,” LSP’s...
...more time in Germany, with Forbion and LSP...
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...autoimmunity company Imcyse S.A. raised EUR 21.3 million ($25.8 million) from existing investors Biogenosis, Epimede, LSP...
BioCentury | Feb 11, 2021
Finance

Belgium’s V-Bio looking for bigger bets in and out of its home country with

...the second fund, V-Bio joins the ranks of other European VCs including BioGeneration Ventures, Forbion, LSP...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...Tokyo:4508), also continues to have a stake in its success.One of the series A investors, LSP...
...say why the neurodegeneration-focused fund invested in a company primarily focused on cardiovascular disease, and LSP...
BioCentury | Jan 12, 2021
Finance

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

...Philip Scheltens to manage fund with €150M goal By Paul Bonanos, Associate Editor European investment firm LSP...
...director of the Alzheimer’s research center at VU University Medical Center in Amsterdam, to manage the fund.LSP...
...the firm’s portfolio companies.Investors have committed the first €50 million ($60.8 million) toward the fund, which LSP...
BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...stake to Angelini and remains eligible for milestones. Other investors in Arvelle include NovaQuest Capital Management, LSP...
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...firms that raised record funds (Andera, Forbion, Gilde, Kurma, LSP, Medicxi...
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...least two other European life sciences VCs — LSP and Gilde...
BioCentury | Sep 1, 2020
Politics, Policy & Law

FDA’s credibility on the line, plus biotech’s venture wave and a Back to School preview: a BioCentury podcast

...such as Andera Partners, Gilde Healthcare Partners and LSP...
...round by next year. And we saw LSP...
BioCentury | Aug 6, 2020
Finance

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

...two -- LSP and Gilde Healthcare Partners -- closing funds larger than $400 million (see “LSP...
Items per page:
1 - 10 of 283
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...finance biotechs, especially the more mature rounds,” LSP’s...
...more time in Germany, with Forbion and LSP...
BioCentury | Feb 17, 2021
Deals

Feb. 17 Quick Takes: Vir, GSK expand partnership; plus Nektar; ImmuneID, Imcyse, Provention-Huadong and Novartis-Gates

...autoimmunity company Imcyse S.A. raised EUR 21.3 million ($25.8 million) from existing investors Biogenosis, Epimede, LSP...
BioCentury | Feb 11, 2021
Finance

Belgium’s V-Bio looking for bigger bets in and out of its home country with

...the second fund, V-Bio joins the ranks of other European VCs including BioGeneration Ventures, Forbion, LSP...
BioCentury | Jan 15, 2021
Finance

Armed with newer data, $196M, NewAmsterdam hopes to resuscitate well-traveled CETP dyslipidemia program

...Tokyo:4508), also continues to have a stake in its success.One of the series A investors, LSP...
...say why the neurodegeneration-focused fund invested in a company primarily focused on cardiovascular disease, and LSP...
BioCentury | Jan 12, 2021
Finance

Seeking to fill gap in the clinic, LSP raises €50M toward dementia-focused fund

...Philip Scheltens to manage fund with €150M goal By Paul Bonanos, Associate Editor European investment firm LSP...
...director of the Alzheimer’s research center at VU University Medical Center in Amsterdam, to manage the fund.LSP...
...the firm’s portfolio companies.Investors have committed the first €50 million ($60.8 million) toward the fund, which LSP...
BioCentury | Jan 4, 2021
Deals

Angelini adds registrational epilepsy program via $610M Arvelle takeout

...stake to Angelini and remains eligible for milestones. Other investors in Arvelle include NovaQuest Capital Management, LSP...
BioCentury | Jan 1, 2021
Deals

The good, the bad and the COVID: BioCentury’s playlist for pandemic times

...firms that raised record funds (Andera, Forbion, Gilde, Kurma, LSP, Medicxi...
BioCentury | Dec 12, 2020
Finance

Forbion to focus record €460M fund on early-stage opportunities

...least two other European life sciences VCs — LSP and Gilde...
BioCentury | Sep 1, 2020
Politics, Policy & Law

FDA’s credibility on the line, plus biotech’s venture wave and a Back to School preview: a BioCentury podcast

...such as Andera Partners, Gilde Healthcare Partners and LSP...
...round by next year. And we saw LSP...
BioCentury | Aug 6, 2020
Finance

‘Not drip-feeding’: Andera looks to deploy record €450M fund to mostly European biotechs

...two -- LSP and Gilde Healthcare Partners -- closing funds larger than $400 million (see “LSP...
Items per page:
1 - 10 of 283